01
Cash & equivalents decreased 17.3%
Cash & equivalents changed -17.3% from the comparable as-filed period.
$26.8M→$22.2MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTNuvectis Pharma, Inc.'s latest supported as-filed period reports net income of -$7.0M, 10.8% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -17.3% from the comparable as-filed period.
Net income changed -10.8% from the comparable as-filed period.
Operating income changed -9.1% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
NVCT · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-099712SEC ↗4Aug 5, 2026Period Aug 3, 20260001104659-26-091279SEC ↗10-QAug 4, 2026Period Jun 30, 20260001104659-26-090109SEC ↗8-KAug 4, 2026Period Aug 4, 20260001104659-26-090094SEC ↗4Jul 1, 2026Period Jun 30, 20260001104659-26-079793SEC ↗4Jul 1, 2026Period Jun 30, 20260001104659-26-079792SEC ↗8-KJun 30, 2026Period Jun 29, 20260001104659-26-079360SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 3, 2026Filed Aug 5, 2026 | Carson Michael J.Vice President, Finance | Grant Or AwardDirect | 30,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +29.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001104659-26-078823